INSTITUT CURIE

Egle Therapeutics has received €9.3 million in non-dilutive funding from France 2030's "Innovations in Biotherapies and Bioproduction" initiative to accelerate development of its lead immuno-oncology candidate EGL-001.

• TKIs target the intracellular kinase domain of HER2, inhibiting cell proliferation pathways, while ADCs utilize antibodies to deliver cytotoxic payloads directly to cancer cells. • HER2-directed ADCs demonstrate broader efficacy across various HER2 alterations, including mutations, amplifications, and overexpression, offering versatile treatment options. • TKIs offer advantages of oral administration and established safety profiles, though their effectiveness can vary depending on specific HER2 mutations in the ATP binding domain.

Valerio Therapeutics has acquired Emglev Therapeutics, gaining access to innovative single-domain antibody (sdAb) technology that enables fully human antibody development through in vitro processes.

The VESPER trial's molecular subtyping analysis reveals the BaSq subtype (pure or mixed) is associated with decreased progression-free survival and overall survival in bladder cancer patients.

• The LUMINOSITY trial showed telisotuzumab vedotin (Teliso-V) yielded a 29% response rate in patients with c-Met-overexpressing, EGFR wild-type, nonsquamous NSCLC. • Patient-reported outcomes from LUMINOSITY indicated improvements in key cancer-related symptoms like cough and chest pain with Teliso-V treatment. • The trial also demonstrated that Teliso-V maintained quality of life and physical functioning, particularly in patients achieving disease control. • Peripheral neuropathy, a notable side effect, was reported by patients, highlighting the need for proactive management in subsequent trials.